Key Takeaways
- FDA reviewers and scientists continue to write guidances, but publication has slowed substantially since the Trump Administration took office.
Development of US Food and Drug Administration guidances to help speed generic drugs to market has almost stopped since layoffs...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?